William J. Gradishar MD
|
|
- Berenice Weaver
- 6 years ago
- Views:
Transcription
1 Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer Care Robert H. Lurie Comprehensive Cancer Center
2
3 Recurrence hazard rate The Long Tail of ER-Positive Breast Cancer Initial Peak ER/PgR+ (n=2257) ER/PgR (n=1305) Long Tail PgR = progesterone receptor. Saphner et al. J Clin Oncol. 1996;14:2738. Years
4 Recurrence hazard rate Risk of Breast Cancer Recurrence: Two Cell Populations )Proliferating Micromets (CT-sensitive) ER/PgR+ ER/PgR 2)Relapsing Dormant Cells PgR = progesterone receptor. Saphner et al. J Clin Oncol. 1996;14:2738. Years
5 FDA-Indications: Tamoxifen The most important drug worldwide for hormone receptor positive breast cancer Adjuvant postmenopausal node+ Postmenopausal metastatic Premenopausal metastatic Adjuvant node negative Male metastatic Prevention DCIS
6 TAMOXIFEN 2010 EBCTCG OVERVIEW TAMOXIFEN VS NOT 1 yr vs not 2 yr vs not 5 yr vs not EBCTCG OVERVIEW No of women LONGER VS SHORTER TAM 2 4 vs 1 2 y 5 vs 1-2 y 10 vs 5 y No of women Median follow-up = 15y 22% are ER- PR- Median follow-up = 5y 50% are ER?
7 2010 EBCTCG OVERVIEW 5y in ER+ disease TAMOXIFEN Reduces Recurrence by 38%, BC death by 30% All deaths by 22% Contralateral BC by 40% Benefits all women with ER+ disease Unclear benefits in ER-PgR+ disease Benefits women with ER very rich tumors more Increases endometrial cancer by 2.3 fold
8 2010 EBCTCG OVERVIEW Tamoxifen for 5y: Benefits in subgroups
9 2010 EBCTCG OVERVIEW Tamoxifen for 5y vs same management but no Tam
10 2010 EBCTCG OVERVIEW?
11 2010 EBCTCG OVERVIEW Tamoxifen for 5y : Benefit over time
12 5 years of tamoxifen versus no tamoxifen* RECURRENCE ER+ BREAST CANCER MORTALITY Recurrence Yrs 0-4 Yrs 5-9 Yrs 9-14 Reduction 47% 31% 4% p< p< p=0.7 BrCaMort. Yrs 0-4 Yrs 5-9 Yrs 9-14 Reduction 29% 33% 34% p< p< p< *EBCTCG, Lancet 2011; 378:
13 Optimal Duration of Tamoxifen
14 % of patients % of patients NSABP B-14: No Benefit of Extending Tamoxifen Beyond 5 Years DFS OS Placebo Tamoxifen P= % 78% Placebo Tamoxifen P= % 91% Years Years 7 Tamoxifen arm had higher rates of endometrial cancer, and more deaths from ischemic heart disease and cerebrovascular disease. Fisher B. J Natl Cancer Inst. 2001;93:
15 20,187 women with ER-positive or ERunknown disease randomised in 5 trials of 10 vs 5 years of tamoxifen: ECOG, Scottish & NSABP B-14 1,588 ATLAS* 11,646 attom 6,953 ALL TRIALS 20,187 *ATLAS, Lancet 2013; 381:
16 Number randomised/year Recruitment by ER status Year of randomisation
17 10 vs 5 years of tamoxifen: effect on breast cancer recurrence ASCO vs 456 recurrences RR=0.95 (95%CI ) p=ns
18 10 vs 5 years of tamoxifen: Recurrence by treatment ASCO vs 672 recurrences RR=0.85 (95%CI ) p=0.003 An additional 143 vs 216 recurrences since 2008
19 10 vs 5 years of tamoxifen: Recurrence by year of follow-up
20 10 vs 5 years of Tamoxifen: Breast Cancer Death by Treatment Allocation 404 vs 452 breast cancer deaths RR=0.88 (95%CI ; p=0.05) p=0.06
21 10 yrs vs 5 yrs BREAST CANCER MORTALITY IN ER+ rate ratio* by period in attom and ATLAS 10 yrs tam. vs 5: attom trial (n=6934 ER+/UK) 10 yrs tam. vs 5: ATLAS trial* (n=10,543 ER+/UK) 10 yrs tam. vs 5: attom & ATLAS combined (n=17,477 ER+/UK) years ( ) 0.92 ( ) 0.97 ( ) years ( ) 0.75 ( ) 0.75 ( ) All years 0.88 ( ) 0.83 ( ) 0.85 ( ) p=0.007 p=0.002 p= p=0.1 p=0.004 p=0.001 *Inverse variance weighted estimate of the effect in ER+.(ATLAS, Lancet 2013)
22 ER+ 10 yrs vs 5 yrs OVERALL SURVIVAL rate ratio* by period in attom and ATLAS 10 yrs tam. vs 5: attom & ATLAS combined (n=17477 ER+/UK) years ( ) years ( ) All years 0.91 ( ) p= p=0.008 *Inverse variance weighted estimate of the effect in ER+ (ATLAS, Lancet 2013)
23 [TITLE] Presented By Rebecca Alexandra Dent, MD at 2013 ASCO Annual Meeting
24 [TITLE]
25 Tamoxifen (TAM) 4-hydroxy-TAM CYP3A N-desmethyl-TAM Genetic Variants, Inhibitors Stearns et al. JNCI 2003;95: Reduced concentrations of Endoxifen, 4-hydroxy-N-desmethyl- TAM (Endoxifen) Active and Abundant Antiestrogen
26 Time to Recurrence According to CYP2D6 Metabolizer Status in Women Receiving Adjuvant Tamoxifen 100 Alleles examined: *3, *4, *5, *6, *10, *17, *41 80 (n=108) % EM/EM, EM/IM EM/PM, IM/IM, PM/IM PM/PM P< Years after randomization Goetz et al., Updated NCCTG , SABCS 2008 HR 4.0 PM relative to EM (n=65) (n=16)
27 Agency for Healthcare Research and Quality (AHRQ) Analysis (2010) There were no consistent associations between CYP2D6 polymorphisms and outcomes in tamoxifen treated women with breast cancer across 16 studies included in this systemic review.
28 International Tamoxifen Pharmacogenomics Consortium Overall data from 4804 patients, 2880 after exclusions; adjuvant ER+ Main findings: No difference in DFS based on CYP2D6 status (p = 0.73) No difference in OS based on CYP2D6 status (p = 0.69)
29 Abstract S1-8; Leyland-Jones: CYP2D6 in BIG 1-98 BIG 1-98 S U R G E R Y Stratify Institution CT (Adjuvant/ Neoadjuvant) -Prior -None -Concurrent R A N D O M I Z E R A N D O M I Z E A B A B C D Tamoxifen Letrozole 2-Arm Option Tamoxifen Letrozole 4-Arm Option Tamoxifen Letrozole Letrozole Tamoxifen N=911 N=917 N=1548 N=1546 N=1548 N=1540 N=1,828 Enrolled N=6,182 Enrolled N=8, YEARS Monotherapy Population N=4,922 (2459 T; 2463 L) 76 Months Median Follow-Up
30 Outcome by CYP2D6 TAMOXIFEN No Chemotherapy 9% PM 27% IM
31 ASCO Guidelines
32
33 % of patients % of patients Significant risk of recurrence remains even with tamoxifen therapy Recurrences Breast cancer deaths 15% 17% 9% 18% Tamoxifen Control 20 Tamoxifen Control Years Years Adapted with permission. Early Breast Cancer Trialists Collaborative Group Meeting, 2000 Early Breast Cancer Trialists Collaborative Group. Lancet. 2005;365:
34 Initial adjuvant trial Adjuvant Aromatase Trials Randomization Tamoxifen Aromatase inhibitor Trial ATAC, BIG 1-98 Randomization Randomization Switching trial 2-3 years prior tamoxifen Tamoxifen Aromatase inhibitor ARNO 95, ITA, IES ABCSG 8 Randomization Upfront vs. Switching Initial and sequencing trial Extended adjuvant trial Tamoxifen Aromatase inhibitor Aromatase inhibitor Tamoxifen Aromatase inhibitor Tamoxifen Aromatase inhibitor Tamoxifen Aromatase inhibitor Randomisation MA.17, ABCSG-6A, NSABP B-33 5 years prior tamoxifen 0 Time (years) 5 TEAM BIG 1-98 Aromatase inhibitor Placebo
35 Third-Generation AIs NC N N N N N N Exemestane O Letrozole NC H 3 C CN CH 3 H 3 C CH 3 O CN Anastrozole CH 2 Third Generation AIs High Selectivity Efficacy Safety Profile
36 Adjuvant Endocrine Trials: Efficacy Aromatase Inhibitor Versus Tamoxifen Strategy RCTs Pts Update Up-Front Early Switch ATAC 6186 Lancet Oncol 2008 Median FU (mo.) AI Efficacy [HR, p] DFS/EFS OS 100 ANA 0.90 (0.025) 1.00 (0.99) BIG JCO LET 0.82 (0.007) 0.91 (>0.05) ITA JCO AGT NR (0.6) NR (0.005) ITA IES 4742 Ann Oncol 2006 Lancet ANA 0.57 (0.005) 0.56 (0.1) 56 EXE 0.76 (0.0001) ARNO JCO ANA 0.66 (0.049) Sequencing ABCSG SABCS (0.08) 0.53 (0.045) 28 ANA 0.76 (0.07) NR Absolute DFS Reductions at 3-6 years Up-Front Early Switch Sequence 2-4 % 3-5% 1.5%
37 Recurrence Rate after Endocrine Therapy in ATAC Trial Cuzick J, et al. Lancet 11:1135, 2010
38 ER+ Breast Cancer: Different Risk Factors for Early and Late Recurrence? Early Recurrence High grade Low ER receptor expression PgR negative HER-2 positive High recurrence score Late Recurrence Low to intermediate grade High ER receptor expression PgR positive or PgR negative HER-2 negative (Low recurrence score) High Disease Burden -- Large Tumor -- Multiple Positive Nodes High Disease Burden -- Large Tumor -- Multiple Positive Nodes
39 Nodal status and tumor size both predictors of recurrence in years 0-5 and Sestak I et al. JNCI 2013; published online Sept 12.
40 Adjuvant Endocrine Trials: Efficacy Aromatase Inhibitor Versus Placebo or No Treatment Strategy RCTs Pts Update Median FU (mo.) AI Efficacy [HR, p] DFS/EFS OS MA JNCI LET 0.58 (0.001) 0.82 (0.3) Extended Switch ABCSG 6a 856 ASCO ANA 0.64 (0.047) NR NSABP B JCO EXE 0.68 (0.07) 1.20 (0.64) Absolute DFS reductions at 3-6 years Extended Switch 6%
41 MA.27 Study Design Eligibility: Postmenopausal ER-positive Early breast cancer Stratification Lymph node status Adjuvant chemotherapy Trastuzumab use Celecoxib use Aspirin use Open-label R A N D O M I Z E Anastrozole 1 mg/day x 5 years N = 7576 patients May 2003 July 2008 Exemestane 25 mg/day x 5 years Study Objectives: Primary: Event-free survival (EFS) Secondary: Overall survival (OS), distant disease-free survival (DDFS), time to distant recurrence, incidence of contralateral breast cancer, incidence of clinical fractures, evaluation of breast density, cardiovascular events, toxicities, quality of life Goss PE, et al. Cancer Res. 2010;70(24 Suppl): Abstract S
42 MA.27: Secondary Efficacy Outcomes Outcome Number (%) of Events Exemestane Anastrozole Stratified HR (95% CI) P Value OS 208 (5.5) 224 (5.9) 0.93 ( ).64 DDFS 157 (4.1) 164 (4.3) 0.95 ( ).46 DSS 89 (2.4) 98 (2.6) 0.93 ( ).62 CI = confidence interval; DDFS = distant recurrence; DSS = disease-specific survival; HR = hazard ratio; OS = overall survival Goss PE, et al. Cancer Res. 2010;70(24 Suppl): Abstract S
43 FACE: Letrozole vs Anastrozole Clinical Evaluation Phase IIIb Head-to-Head Comparison Study Design EBC ER+ Postmenopausal Node+ Postmenopausal FSH/LH/E 2 levels De novo adjuvant ET R A N D O M I Z E Letrozole 2.5 mg/qd Anastrozole 1 mg/qd N=~4000 Primary end point DFS Secondary end points Safety OS Time to distant metastasis Time to contralateral disease Breast cancer specific survival FSH = follicle-stimulating hormone; LH = luteinizing hormone; ET = endocrine therapy.
44 NCCN Version
45 Questions to settle! Is there still a role for tamoxifen? Yes Are all Aromatase Inhibitors the same and superior to tamoxifen? If used with tamoxifen, is there an optimal sequence? Is there an optimal duration of therapy?
46 Do All ER+ Tumors Benefit Equally from Extended Adjuvant Therapy?
47 HR MA.17: Efficacy by ER and PgR Status Exploratory retrospective analysis of efficacy (DFS, distant DFS, OS) of letrozole vs placebo in MA.17 according to ER and PgR status* HR (95% Cl), letrozole vs placebo ( ) ( ) +ER+/PgR (n=3809/5187) 73% ER+/PgR (n=636/5187) 12% ( ) ( ) ( ) ( ) DFS DDFS OS *Receptor positivity defined as 10 fmol/mg protein, or a positive immunocytochemical assay; only 8 patients had ER /PgR status. Update of Goss et al. Breast Cancer Res Treat. 2005;94(suppl 1):S98. Abstract 2042.
48 BIG 1-98 Monotherapy Update Median Follow-up 76 months A B 2-Arm Option Tamoxifen Letrozole N=911 N=917 N=1,828 Enrolled Arm Option N=4,922 A B C Tamoxifen Letrozole Tamoxifen Letrozole N=1548 N=1546 N=3,094 Enrolled D Letrozole Tamoxifen YEARS
49 BIG 1-98 Monotherapy Update Median Follow-up 76 months *Let:Tam: breast cancer events, 321:363 second (non breast) malignancy, 101:115 deaths without prior cancer event, 87:87
50 Filho, et al. SABCS 2012
51
52 BIG 1-98 Letrozole vs Tamoxifen: OS Regan MM, Lancet Oncology, 2012
53 Breast Cancer Events Tam Let vs. Let Overall By Nodal Status* *42% of the population is node positive; 58% node negative
54 Breast Cancer Events Let Tam vs. Let Overall By Nodal Status* *42% of the population is node positive; 58% node negative
55 Questions to settle! Is there still a role for tamoxifen? Yes Are all Aromatase Inhibitors the same and superior to tamoxifen? If used with tamoxifen, is there an optimal sequence? Is there an optimal duration of therapy?
56 [TITLE] Presented By Rebecca Alexandra Dent, MD at 2013 ASCO Annual Meeting
57 No Benefit If Not Taking The Drug!
58 [TITLE]
59 [TITLE]
60 [TITLE]
61 Risk of recurrence at 5 years 38% experience recurrence with no adjuvant treatment (EBCTCG) 50% risk reduction with tamoxifen Further 20 30% risk reduction with AIs EBCTCG Lancet 2005;365:1687
William J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2011 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationThe worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials
The worldwide overview: updated (2005-6) meta-analyses of hormonal treatment trials Richard Gray, for the Early Breast Cancer Trialists Collaborative Group (EBCTCG) Main questions, 2005-6 1) 5 years of
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationATAC Trial. 10 year median follow-up data. Approval Code: AZT-ARIM-10005
ATAC Trial 10 year median follow-up data Approval Code: AZT-ARIM-10005 Background FDA post-approval commitment analysis to update DFS, TTR, OS and Safety Prof. Jack Cuzick on behalf of ATAC/LATTE Trialists
More informationAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & Chair NR Committee
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationEndocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment
Review Article Page 1 of 12 Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment Jun-Jie Li, Zhi-Min Shao Department of
More informationShould premenopausal HR+ve breast cancer receive LHRH?
Should premenopausal HR+ve breast cancer receive LHRH? Hesham Elghazaly, MD Prof. Clinical Oncology, Ain Shams University President of the BGICS Should premenopausal HR+ve breast cancer receive LHRH? NO?
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationКой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго?
Кой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго? д-р Красимир Койнов МБАЛ Сердика, София Декларация Консултации и хонорари: Roche, Boerhinger Ingelheim, Astra
More informationStart strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer
Available online at www.sciencedirect.com Biomedicine & Pharmacotherapy 63 (2009) 1e10 Short review Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 67 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More information6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer
6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer Saad J. Sirop, MD James N. Ingle, MD Matthew P. Goetz, MD Introduction
More informationTerapia Hormonal da Paciente Premenopausa
I Congresso de Oncologia D Or 5 e 6 de julho de 2013 Terapia Hormonal da Paciente Premenopausa Antonio C. Wolff, MD, FACP, FASCO Professor de Oncologia Programa de Câncer de Mama Johns Hopkins University
More informationThe Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer
The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer Erin Roesch, MD, and Claudine Isaacs, MD Abstract Endocrine therapy in the adjuvant setting
More informationPublished Ahead of Print on July 12, 2010 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on July 12, 2010 as 10.1200/JCO.2009.26.3756 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2009.26.3756 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A
More informationScottish Medicines Consortium
Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationEndocrine Therapy for Early Breast Cancer: Updated Review
REVIEWS AND CONTEMPORARY UPDATES Ochsner Journal 17:405 411, 2017 Ó Academic Division of Ochsner Clinic Foundation Endocrine Therapy for Early Breast Cancer: Updated Review Alexander Tremont, DO, 1 Jonathan
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationGiuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups
Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationAdjuvant Hormonal Therapy in Peri- and Postmenopausal. Breast Cancer
Breast Cancer Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer Paula D. Ryan, Paul E. Goss Massachusetts General Hospital, Boston, Massachusetts, USA Key Words. Breast cancer Aromatase
More informationAdvances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD
Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationNuove strategie nella chemioprevenzione e nella terapia ormonale del carcinoma mammario
University of L Aquila Nuove strategie nella chemioprevenzione e nella terapia ormonale del carcinoma mammario Paolo Marchetti Issues of chemoprevention A New Way to Treat Cancer Before It Happens Prevention:
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationLate Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier. Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program
Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program Conflicts of Interest Research Funding Menarini/Silicon Biosystems(Manufacturer
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationMP Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast Cancer. Related Policies None
Medical Policy Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast BCBSA Ref. Policy: 2.04.36 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section:
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29317 holds various files of this Leiden University dissertation. Author: Nes, Johanna Gerarda Hendrica van Title: Clinical aspects of endocrine therapy
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationAssays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 1/2019 Origination: 1/2006 Next Review: 9/2019 Policy
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationThe efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
More informationAdjuvant Endocrine Therapy for Women With Hormone Receptor Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
ASCO special article abstract ASSOCIATED CONTENT Appendix Data Supplement Author affiliations and support information (if applicable) appear at the end of this article. Accepted on September 17, 2018 and
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More informationA review of adjuvant hormonal therapy in
REVIEW Endocrine-Related Cancer (2004) 11 391 406 A review of adjuvant hormonal therapy in breast cancer Kellie L Jones and Aman U Buzdar 1 Department of Pharmacy, University of Texas M.D. Anderson Cancer
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More information1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical
1 2 1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast
More informationAdjuvant treatment for early breast cancer
Annals of Oncology 16 (Supplement 2): ii182 ii187, 2005 doi:10.1093/annonc/mdi709 Adjuvant treatment for early breast cancer I. Smith The Royal Marsden Hospital, London, UK Introduction Survival rates
More informationThe first randomized clinical trial of adjuvant
ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER Aman U. Buzdar, MD* ABSTRACT The safety and efficacy of tamoxifen as adjuvant endocrine therapy for postmenopausal patients
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Hormonal therapies for the adjuvant treatment of early oestrogen-receptor positive breast cancer The overview is written by members of the
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More information